• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Indian Journal of Endocrinology and Metabolism >Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kerala cohort of the A1chieve study
【24h】

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kerala cohort of the A1chieve study

机译：地特胰岛素，双相门冬胰岛素和门冬胰岛素在2型糖尿病患者中的临床经验：来自A1chieve研究的喀拉拉队列的结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background:The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents.Materials and Methods:Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Kerala, India.Results:A total of 1732 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n = 1203), insulin detemir (n = 212), insulin aspart (n = 312), basal insulin plus insulin aspart (n = 1) and other insulin combinations (n = 1). At baseline glycaemic control was poor for both insulin na?ve (mean HbA1c: 10.0%) and insulin user (mean HbA1c: 8.3%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA1c (insulin na?ve: ?2.4%, insulin users: ?0.5%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.Conclusion:Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
机译：背景：A1chieve是一项多中心研究（28个国家/地区），为期24周，进行了非干预性研究，评估了地特米尔，双相门冬氨酸和门冬胰岛素在2型糖尿病患者中的安全性和有效性（n = 66,726），涉及四个领域材料和方法：在基线，第12周和第24周收集数据。简短的交流提供了来自印度喀拉拉邦的患者的研究结果。结果：共有1732名患者被纳入研究。在研究中使用了四种不同的胰岛素类似物方案。患者已开始或改用双相门冬胰岛素（n = 1203），地替米胰岛素（n = 212），门冬胰岛素（n = 312），基础胰岛素加门冬胰岛素（n = 1）和其他胰岛素组合（n = 1）。在基线时，纯胰岛素组（平均HbA1c：10.0％）和胰岛素使用者（平均HbA1c：8.3％）组的血糖控制均较差。治疗24周后，两组患者的HbA1c均改善（胰岛素纯：2.4％，胰岛素使用者：0.5％）。结论：开始或改用胰岛素类似物与血糖控制改善，低血糖发生率低有关，因此没有发生包括重大降血糖事件或发作在内的SADR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号